gentuximab + paclitaxel

Gentuximab + paclitaxel is an investigational combination therapy consisting of **gentuximab**, a monoclonal antibody, and **paclitaxel**, a small molecule chemotherapeutic agent. This regimen is being studied for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma after failure of first-line therapy. Gentuximab is designed to target specific tumor antigens, though its precise target has not been disclosed in public sources as of this time. Paclitaxel stabilizes microtubules, inhibiting cell division and promoting apoptosis in tumor cells. The combination exploits gentuximab's potential for targeted tumor suppression and paclitaxel's anti-mitotic action to potentially enhance anti-tumor efficacy. The regimen is administered intravenously[3][6].